Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B. Johnson, Justin M. Balko, Violeta Sánchez et al.|Nature Communications|2016Cited by 572
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug TreatmentJoe T. Sharick, Melissa C. Skala, Christine M. Walsh et al.|Frontiers in Oncology|2020Cited by 144